Ensysce Biosciences raises $21M in initial tranche, meets Nasdaq equity rules, seeks second bid-price grace period
Ensysce Biosciences raised $21M in the first tranche of its Series C financing, issuing 120,260 shares for a total $43M. The company meets Nasdaq equity rules and seeks a second 180-day grace period. It believes it has at least $2.5M in stockholders' equity, satisfying Nasdaq's requirements.
How this was made
The 30-second read
Why it matters
The $21M infusion resolves a Nasdaq Listing Rule 5550(b)(1) deficiency, reducing immediate delisting risk.
Market read
Capital raise removes a compliance hurdle, potentially stabilizing the stock.
What to watch
Milestone‑dependent second tranche could be delayed, affecting future liquidity.
Background
Ensysce Biosciences is a clinical‑stage biotech listed on Nasdaq, recently facing equity compliance issues.
Ticker impact
Ensysce Biosciences disclosed raising over $21M in a Series C preferred financing, meeting Nasdaq equity requirements.
Potential modest upside as the raise resolves listing deficiency.
Funding alleviates immediate Nasdaq compliance risk, but the amount is modest for a micro‑cap biotech.
Market effects
May improve sentiment for small‑cap biotech financing activity.
Limited to U.S. Nasdaq‑listed micro‑caps.
Low
Counterpoint
The raise may signal cash burn concerns, suggesting caution.
Key entities
- companyEnsysce Biosciences
Nasdaq‑listed biotech issuing Series C preferred shares.
